Cochrane · systematic review · CD010452
Treatment of enteric fever (typhoid and paratyphoid fever) with cephalosporins
Kuehn, R, Stoesser, N, Eyre, D, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
14
No studies
7
Included studies
NR
No studies 7 · 33.3%Ungraded 0 · 0%Very low 7 · 33.3%Low 7 · 33.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cefixime versus fluoroquinolones for treating enteric fever
Population: adults and children with enteric fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical failure Cefixime vs fluoroquinolones | RR 13.39 [3.24, 55.39] | 2 studies · 240 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Microbiological failure Cefixime vs fluoroquinolones | RR 4.07 [0.46, 36.41] | 2 studies · 240 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Relapse Cefixime vs fluoroquinolones | RR 4.45 [1.11, 17.84] | 2 studies · 220 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Time to defervescence Cefixime vs fluoroquinolones | MD 1.74 [0.5, 2.98] | 3 studies · 425 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Duration of hospital stay Cefixime vs fluoroquinolones | no estimate extracted | NR | No studies |
Convalescent faecal carriage Cefixime vs fluoroquinolones | no estimate extracted | NR | No studies |
Serious adverse events Cefixime vs fluoroquinolones | no estimate extracted | NR | No studies |
Ceftriaxone versus azithromycin for treating enteric fever
Population: children under 18 years of age with enteric fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical failure Ceftriaxone vs azithromycin | RR 0.42 [0.11, 1.57] | 3 studies · 196 participants | Low Downgraded: risk of bias, imprecision |
Microbiological failure Ceftriaxone vs azithromycin | RR 1.95 [0.36, 10.64] | 3 studies · 196 participants | Very low Downgraded: risk of bias, imprecision |
Relapse Ceftriaxone vs azithromycin | RR 10.05 [1.93, 52.38] | 3 studies · 185 participants | Very low Downgraded: risk of bias, imprecision |
Time to defervescence Ceftriaxone vs azithromycin | no estimate extracted | 3 studies · 196 participants | Low Downgraded: risk of bias, imprecision |
Duration of hospital stay Ceftriaxone vs azithromycin | no estimate extracted | NR | No studies |
Convalescent faecal carriage Ceftriaxone vs azithromycin | no estimate extracted | NR | No studies |
Serious adverse events Ceftriaxone vs azithromycin | no estimate extracted | NR | No studies |
Ceftriaxone versus fluoroquinolones for treating enteric fever
Population: adults and children with enteric fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical failure Ceftriaxone vs fluoroquinolones | RR 3.77 [0.72, 19.81] | 4 studies · 359 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Microbiological failure Ceftriaxone vs fluoroquinolones | RR 1.65 [0.4, 6.83] | 3 studies · 316 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Relapse Ceftriaxone vs fluoroquinolones | RR 0.95 [0.31, 2.92] | 3 studies · 297 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Time to defervescence Ceftriaxone vs fluoroquinolones | MD 2.73 | 3 studies · 285 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Duration of hospital stay Ceftriaxone vs fluoroquinolones | no estimate extracted | 1 study · 47 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Convalescent faecal carriage Ceftriaxone vs fluoroquinolones | RR 0.18 [0.01, 3.72] | 1 study · 73 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Serious adverse events Ceftriaxone vs fluoroquinolones | no estimate extracted | NR | No studies |